New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:03 EDTDCTH, ATRSAntares Pharma announces resignation of CEO Wotton, names Hobbs as CEO
Antares Pharma (ATRS) announced the resignation of Paul K. Wotton, Ph.D. who informed the company’s Board of Directors that he will assume the position of CEO of a development stage biotechnology company. Wotton also has resigned from the Antares Board of Directors. Antares Pharma also announced today the appointment of Eamonn P. Hobbs to the position of President and CEO of the company effective immediately. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Hobbs was previously the President and CEO of Delcath Systems (DCTH).
News For ATRS;DCTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
17:03 EDTDCTHMitchell Kopin reports 6.7% passive stake in Delcath Systems
July 20, 2015
08:07 EDTDCTHDelcath Systems's melphalan granted Orphan Drug Designation by FDA
Delcath Systems announced that the FDA Office of Orphan Products Development, or OOPD, has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use